Skip to main content
. 2021 Jun 9;27(17):4848–4858. doi: 10.1158/1078-0432.CCR-20-4219

Figure 5.

Figure 5. Association between molecular subgroups (FGF- and VEGF-enriched groups vs. FGF- and VEGF-intermediate groups) identified using the angiogenic and growth factor gene-expression profile and OS in the lenvatinib (A) and sorafenib (B) arms. ANG2, angiopoietin-2; C, cycle; CI, confidence interval; D, day; FGF, fibroblast growth factor; HR, hazard ratio; LEN, lenvatinib; OS, overall survival; SOR, sorafenib; VEGF, vascular endothelial growth factor.

Association between molecular subgroups (FGF- and VEGF-enriched groups vs. FGF- and VEGF-intermediate groups) identified using the angiogenic and growth factor gene-expression profile and OS in the lenvatinib (A) and sorafenib (B) arms. ANG2, angiopoietin-2; C, cycle; CI, confidence interval; D, day; FGF, fibroblast growth factor; HR, hazard ratio; LEN, lenvatinib; OS, overall survival; SOR, sorafenib; VEGF, vascular endothelial growth factor.